Tag Archives: religion

Sunday Space + Two Full Days of RESI JPM

16 Dec

By Sougato Das, President and COO, LSN

Sougato-Das

RESI JPM 2026 expands the opportunity to connect by adding Sunday partnering and event space, giving attendees an early start to JPM Week. With RESI JPM running Monday–Tuesday, Sunday provides a strategic window to schedule investor meetings, host receptions, or bring teams together while momentum is already building across San Francisco.

RESI JPM is the only JPM conference where 700+ investors actively providing seed to Series B funding attend, alongside in-licensors seeking preclinical through Phase 2 assets. For preclinical and clinical-stage biotech, medtech, diagnostic, digital health, and AI companies, RESI JPM remains the most efficient way to connect with aligned investors and strategic partners during JPM Week. Many companies schedule 10–20 meetings in a single day, making partnering the core of the RESI experience.

New Sunday Partnering Opportunities Added

Life Science Nation is announcing additional partnering slots on Sunday, January 11, hosted at the Marriott Marquis. These meetings take place ahead of the main conference and allow attendees to secure valuable investor conversations before calendars fill up.

The Sunday Partnering Slot sign-up form is available to RESI attendees, allowing registered participants to request meetings and plan their schedules in advance.

Start JPM Week with Purpose

This added day gives companies a head start to:

  • Schedule investor or in-licensor meetings
  • Connect with fellow RESI attendees
  • Host private meetings or team gatherings

Located in the center of the JPM ecosystem, the Marriott Marquis offers a convenient and efficient setting to begin JPM Week with focused, high-value interactions.

With Sunday now in play, RESI JPM 2026 delivers more time, more access, and more opportunities to make meaningful connections before the week reaches full pace.

Register for RESI JPM 2026

Tags: , , , , , , , , , , , , , , , , , , ,

RESI 2026 Series: Connecting Life Science Innovators with Capital and Partners 

25 Nov

By Sougato Das, President and COO, LSN

Sougato-Das

The RESI 2026 Series continues Life Science Nation’s commitment to providing consistent, high-quality partnering opportunities for life science and healthcare innovators. Designed to connect startups with investors and strategic partners that align by sector, indication, and stage of development, each RESI conference offers a structured environment for founders navigating an increasingly competitive fundraising landscape.

Throughout the 2026 Series, attendees will find a familiar mix of investor panels, expert-led workshops, the Innovator’s Pitch Challenge, and a partnering system built to support targeted outreach and productive meetings. These elements work together to help companies strengthen their messaging, expand their networks, and identify capital sources that are the best fit for their technologies.

As scientific progress accelerates and capital deployment becomes more selective, the RESI 2026 Series serves as a reliable forum for global stakeholders to exchange insights, source opportunities, and build lasting relationships across the life science ecosystem.

Find registration information at RESIConference.com. If you are interested in RESI sponsorship, please contact us.

Tags: , , , , , , , , , , , , , , , , , , ,

RESI London 2025: Dec 4! See feedback from previous attendees about the UK’s biggest investment conference!

21 Oct

By Sougato Das, President and COO, LSN

Sougato-Das

RESI London 2025 will be the second year of the UK’s biggest life science investor conference. We expect 250 investors, ready to finance your company. The RESI partnering system allows you to schedule face to face meetings with each investor. See what last year’s attendees are saying!

Testimonials

“RESI London was an extremely productive experience for my company, and the partnering system was so easy to use.”

– Nick Sireau, CEO, Serenatis Bio

“RESI is the go-to meeting for biotech CEOs’ seeking early stage capital. They have built an early stage platform educating founders and bringing capital to them. They are the only people serving this under loved sub sector with such passion.”

– Sunil Shah, CEO, O2h Ventures & Co-founder, O2h Group

“Attending RESI London for the first time was a refreshing and highly positive experience. The event exceeded my expectations in several ways. The atmosphere was welcoming and collaborative, which created a conducive environment for meaningful interactions. What stood out most was the exposure to a unique group of investors—those with a specific interest in early-stage, cutting-edge technologies. These are exactly the type of investors we aim to connect with at Rinri, so the conference provided an excellent platform to engage with individuals who understand the risks and rewards of innovative science-driven ventures.”

– Simon Chandler, CEO, Rinri Therapeutics

“My session was punctual and well-organized. The jury members were thoughtfully selected and provided insightful, constructive feedback that was highly valuable.”

– Christine Ruckenbauer, CBO, RIANA Therapeutics

“I highly value RESI and am grateful for the opportunity both to contribute as a pitch judge, company scouting and the networking opportunities. You have a dynamic network with easy, friendly, professional access. Thanks for all you are doing for the life science and tech development sector.”

– Jill Sorensen, MTEC (Investor)

“As One Nucleus seeks to enable our members to engage with the widest possible investor pool, partnering with RESI London creates a unique opportunity to bring our members into contact with new global early-stage investors to complement the known local investors they meet at all other early-stage pitching events in the UK.”

– Tony Jones, CEO, One Nucleus

“We started this as a grassroots meeting with One Nucleus, and it has been extremely gratifying and rewarding to see our international investors attending because the UK, we know, has some great science that needs to get to the global stage. We are expecting 250+ investors.”

– Dennis Ford, CEO, Life Science Nation

Register RESI London by Friday, October 24 to save £200 on early bird rates!

Register for RESI London Appy to Pitch at RESI London

Tags: , , , , , , , , , , , , , , , , , , ,

Will PubMed be Shutdown? 

15 Oct

By Sougato Das, President and COO, LSN

Sougato-Das

Many in the life sciences research community were spooked when PubMed went down temporarily in March after the Trump administration cut $4 billion in “indirect costs” that supported medical research. More recently, an ominous message appeared on PubMed: “Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed…” Many who use PubMed but not other government websites were probably panicked by this, but a quick look at clinicaltrials.gov, NIH Reporter and even NIH’s main site reveals the same message, while different versions of this message appear on the websites of HHS, CMS, etc.

Still, various EU governments have been quietly preparing for a PubMed shutdown by ensuring they will have a PubMed-alternative just in case. Of course, let’s be real: while they may be able to serve the existing content in PubMed, they will not be able to suddenly support the thousands of additional abstracts and articles added each day, along with MeSH tagging, journal selection, XML/JSON feeds, and other critical functions PubMed provides.

While PubMed is critical to nearly every life science researcher, even those with access to Web of Science, Embase, etc., it is especially critical to early-stage life science companies and investors. For basic research, competitive intelligence, due diligence and more, PubMed is indispensable for those without access to paid literature databases. PubMed is also an important source for pipeline database providers that investors and pharma use to find assets and perform CI.

The US government, for decades, has supplied a critical and reliable literature resource for worldwide audiences, both professional and non-professional alike. With the addition of the first and best clinical trial registry in 2000, continued funding for this resource is paramount for global biomedical research.

Tags: , , , , , , , , , , , , , , , , , , ,

How 100% Pharma Tariffs Could Ripple Through Early-Stage Biotech Investment 

7 Oct

By Sougato Das, President and COO, LSN

Sougato-Das

We have all heard about the recent 100% pharma tariff announcement, applicable mainly to manufacturers or marketed drugs unless they are in the process of building manufacturing facilities in the US. We know that early stage biotechs are generally not counting on investment to take them through manufacturing, for which they will seek a pharma partner. Nevertheless, these tariffs may still have an effect on early-stage biotech investments. Investment in early-stage (seed, Series A/B) biotech is likely to face increased headwinds under a 100 % pharmaceutical tariff regime. The tariff risk exacerbates existing structural challenges in biotech investing.

Overall Expected Effect (Short to Medium Term) 

  • Slower fundraising pace 
    The number of deals may decline, particularly in the earlier stages. Biotech investors will likely become more selective, preferring de-risked assets, strong data, or compelling platforms with clear strategies to mitigate tariff exposure.
  • Higher effective cost of capital 
    Investors will demand more upside or stricter protections (e.g. liquidation preferences, anti-dilution) to compensate for the added risk.
  • Greater emphasis on capital efficiency / leaner burn models 
    Startups may need to conserve cash more, focus earlier on key inflection points, outsource less, and plan fallback strategies for supply chain risk.
  • Longer timelines / delayed exits 
    Because of the risk, uncertainty, and possible delays, the time to IPO, acquisition, or commercialization may stretch, further compressing IRR for investors.
  • Capital flow shift toward infrastructure and enabling technologies 
    Some portion of venture capital may redirect toward bioprocessing, domestic manufacturing, synthetic biology for local API production, supply-chain tools — companies that can help others evade tariff impact.
  • Public market investment in pharma may slow, leading to less IPOs 
    The tariffs could serve to further erode the attractiveness of the biopharma sector for public market investors, reducing the room for IPOs, and pressuring investment taking place more upstream.

In summary, while the recent 100% pharma tariffs certainly don’t have a direct effect on early-stage biotech investing, their dampening effects will nonetheless be felt.

Tags: , , , , , , , , , , , , , , , , ,

Super Early Bird Rates End October 3 for RESI London and RESI JPM 

30 Sep

By Sougato Das, President and COO, LSN

Sougato-Das

Life Science Nation’s Redefining Every Stage of Investments (RESI) conferences are designed to connect life science companies with global investors and strategic partners. Two major upcoming events, RESI London and RESI JPM, are now open for registration at Super Early Bird rates through October 3. By registering early, attendees can save £300 on RESI London and $800 on RESI JPM.

RESI London 2025

The first week of December marks the largest life science partnering and venture week in the UK. If you are raising pre-seed, seed, round A or round B, or are in phase 2 or earlier development, Life Science Nation’s RESI London, One Nucleus’ Genesis, and ELRIG/SLAS events offer stronger partnering, investment, learning, and procurement opportunities compared to the health care week in late November that runs alongside the Jefferies investment banking event. That November week typically focuses on recent IPOs, companies close to IPO, and phase 3 or more advanced companies seeking partnerships. For companies not yet at that stage, December’s conference series is a more strategic use of critical conference and travel budgets.

RESI London and Genesis are joining to provide a multi-day investment, partnering, and thought leadership event for venture-stage companies pursuing funding and strategic alliances. RESI London will take place on December 4 at 1 Wimpole Street and 11 Cavendish Square, followed by two days of virtual partnering on December 5 and 6. Super Early Bird registration is now open, offering a savings of £300 until October 3.

RESI JPM 2026

RESI JPM will be held January 12–13, 2026, at the San Francisco Marriott Marquis. The program features two days of in-person investor panels, workshops, networking, and one-on-one partnering, followed by three days of online partnering on January 14, 19, and 20.

Previous RESI JPM conferences have drawn more than one thousand attendees, including over 500 investors, innovators, and industry experts from across the globe. The conference is held concurrently with JP Morgan Healthcare Week, January 12–15, 2026, which takes place at the Westin St. Francis. Known as the largest healthcare investment symposium worldwide, JPM attracts thousands of life science professionals each year.

Super Early Bird registration for RESI JPM offers a savings of $800 when completed before October 3.

Register for RESI London
Register for RESI & Genesis Combi Ticket		 Register for RESI JPM

Both conferences provide access to global investors and in-licensors, strategic partners, and hundreds of early-stage innovators across therapeutics, medical devices, diagnostics, and digital health. Register now to take advantage of Super Early Bird discounts for RESI London and RESI JPM before October 3.

Tags: , , , , , , , , , , , , , , , ,

China’s Biotech Boom: Innovation, Influence, and Rising Tensions 

5 Aug

By Sougato Das, President and COO, LSN

Sougato-Das

As 2025 progresses, China’s biotech and pharmaceutical sectors are not just growing—they’re reshaping the global industry landscape. With skyrocketing innovation, bold regulatory reform, and a deepening rivalry with the U.S., Chinese biotech firms are asserting their global presence at unprecedented speed. The GSK / Hengrui Pharma deal, involving a major collaboration potentially worth up to $12.5 billion, is the latest example. The deal focuses on developing up to a dozen drug candidates, primarily in respiratory diseases, immunology, infection, and oncology. GSK will pay Hengrui an upfront fee of $500 million, with the potential for significant milestone payments and royalties if the collaboration is successful. China will continue to play a major role in the worldwide biopharma ecosystem as…

China Emerges as a Global Drug Development Powerhouse

  • Record Licensing Activity: China-to-West drug licensing hit a record $41.5 billion in 2024, a staggering 66% jump from the previous year. Nearly 30% of global innovative drug assets now trace their origin to China.
  • Biotech Licensing Leadership: In 2024, 42% of all global biotech licensing deals over $50 million involved Chinese firms—up from 22% in 2023.

Drug Discovery Is Going East

  • Rapid Shift in Molecule Sourcing: One in three externally sourced molecules by global biopharma firms now comes from China—a dramatic rise from virtually none in 2019. Chinese biotech firms are lauded for their speed, efficiency, and low-cost synthesis of new compounds, positioning them as preferred partners for drug discovery.

Clinical Trials and Regulatory Momentum increases in China

  • China’s Clinical Surge: In 2023, nearly 28% of global clinical trial sponsorships originated from China—up from just 4% a decade ago. Registrations alone rose by 26% last year.
  • Faster to Market: Thanks to reforms by China’s National Medical Products Administration (NMPA), investigational new drugs can now be approved for human testing in just 60 working days.
  • FDA Recognition: Chinese trials are increasingly qualifying for FDA priority pathways, challenging the traditional dominance of U.S.-based clinical development.

China is at the Cutting Edge of Gene Editing

  • CRISPR Leadership: Chinese startups like YolTech (in vivo CRISPR therapy) and Huidagene (brain-targeted CRISPR trials) are leading in next-gen gene editing.
  • Global Recognition: According to Goldman Sachs, China is at the forefront of CRISPR and CAR-T research.

Tensions and Regulatory Hurdles deepen with the US

  • Geopolitical Pressure: Proposed U.S. legislation—the BIOSECURE Act—would prohibit drugmakers with federal contracts from using Chinese firms like WuXi AppTec and WuXi Biologics after 2032. This could disrupt global supply chains and complicate R&D strategies for U.S. companies.
  • Scientific Chilling Effect: Fears of increased scrutiny are causing some Chinese and Chinese-American researchers to avoid applying for NIH grants, impacting U.S.-China scientific collaboration.
  • Investment Headwinds: Despite innovation, venture capital investment in Chinese biotech has declined due to geopolitical uncertainty.

Cross-Border Deals Multiply

  • Western Biopharma Engagement: U.S. and European firms are actively pursuing licensing and partnership deals with Chinese biotechs—particularly in ADC and bispecific antibody platforms, expanding beyond oncology.
  • Investor Sentiment Splits: Some U.S. investors advocate for protectionist strategies, while others see China’s rise as an opportunity for strategic alignment and access to novel therapies.

What Does All This Means for the Industry>

China is no longer simply a “fast follower” in biotech. It’s now an originator of breakthrough science, shaping the future of global drug development, even as geopolitical tensions threaten to redraw the map of international collaboration.

As global biopharma leaders and investors reassess their strategies, one thing is clear: ignoring China’s biotech ascent is no longer an option.

Tags: , , , , , , , , , , ,

← Older Entries